← 返回

综合多组学分析揭示 NPC2 和 ITGAV 基因作为胃肠道癌症潜在预后生物标志物

英文原题:Comprehensive Multi-Omics Analysis Reveals NPC2 and ITGAV Genes as Potential Prognostic Biomarkers in Gastrointestinal Cancers.

查看英文原题

Comprehensive Multi-Omics Analysis Reveals NPC2 and ITGAV Genes as Potential Prognostic Biomarkers in Gastrointestinal Cancers.

PubMed 2024/12/01(内容时间) Cancer Rep (Hoboken) Q3 · IF 2.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

因此,我们的生物信息学分析显示,NPC2 和 ITGAV 可能作为潜在的生物标志物,用于判断多种 GICs 的预后,并且也与免疫浸润相关。

研究思路结论见上方概要

胃肠道癌症(GICs)在全球发病率和死亡率方面仍占主导地位。由于缺乏有效且准确的预后生物标志物,许多GICs的预后和治疗结果较差。识别能够有效预测个体临床结局的生物标志物是临床肿瘤学的一项基本挑战。尽管不断发现了一些生物标志物,但其预测准确性相对有限,且治疗用途受到限制。鉴于此,迫切需要发现可靠的生物标志物来预测GIC的预后和结局。

我们评估了人类蛋白质图谱数据集,并确定NPC细胞内胆固醇转运蛋白2(NPC2)和整合素亚基αV(ITGAV)可能是这些癌症的不良预测基因。此外,我们使用GEPIA2、cBioPortal、UALCAN、LinkedOmics、STRING、Enrichr、TISDB、TIMER2.0、hTFTarget、miRTarBase、circBank和药物-基因相互作用数据库对NPC2和ITGAV基因进行了全面系统的分析。

我们的结果发现,NPC2 和 ITGAV 在大多数 GIC 中高表达。上述基因表达与 GIC 的若干临床病理特征以及 LIHC 和 STAD 中较差的预后相关。NPC2 最常见的改变类型是扩增,而 ITGAV 为深度缺失。在 PAAD 和 COAD 中,分别观察到 NPC2 和 ITGAV 显著的启动子高甲基化。在免疫学意义方面,NPC2 和 ITGAV 与TIL(肿瘤浸润淋巴细胞)和巨噬细胞的丰度呈正相关。此外,多种免疫调节剂与这些基因的表达显示出强相关性。目前有 10 种靶向 ITGAV 的小分子药物。

展开英文摘要原文

Gastrointestinal cancers (GICs) continue to dominate in terms of both incidence and mortality worldwide. Due to the absence of efficient and accurate prognostic biomarkers, the prognosis and treatment outcomes of many GICs are poor. Identifying biomarkers to predict individual clinical outcomes efficiently is a fundamental challenge in clinical oncology. Although several biomarkers have been continually discovered, their predictive accuracy is relatively modest, and their therapeutic use is restricted. In light of this, the discovery of reliable biomarkers for predicting prognosis and outcome in GIC is urgently required.

We evaluated the Human Protein Atlas dataset and identified NPC Intracellular Cholesterol Transporter 2 (NPC2) and Integrin Subunit Alpha V (ITGAV) as probable poor predictive genes for these cancers. In addition, we used the GEPIA2, cBioPortal, UALCAN, LinkedOmics, STRING, Enrichr, TISDB, TIMER2.0, hTFTarget, miRTarBase, circBank, and drug-gene interaction database databases to conduct a comprehensive and systematic analysis of the NPC2 and ITGAV genes. RESULT: Our results found high expression levels of NPC2 and ITGAV in most GICs. The aforementioned gene expressions were linked to several clinicopathological characteristics of GICs as well as poorer prognosis in LIHC and STAD. The most common alteration type of NPC2 was amplification, and for ITGAV was deep deletion. Significant promotor hypermethylation was also seen in NPC2 and ITGAV in PAAD and COAD, respectively. For the immunologic significance, NPC2 and ITGAV were positively correlated with the abundance of tumor-infiltrating lymphocytes and macrophages. Furthermore, various immunomodulators showed strong correlations with the expression of these genes. There were currently 10 small molecule drugs targeting ITGAV.

Consequently, our bioinformatics analysis showed that NPC2 and ITGAV might be used as potential biomarkers to determine the prognosis of various GICs and are also related to immune infiltration.

论文信息

作者
Piroozkhah M、Zabihi M、Jalali P、Salehi Z
第一作者单位
Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Centre, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Iran
通讯作者单位
Hematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran.Iran
期刊
Cancer reports (Hoboken, N.J.)2024 Dec
原文标识
PubMed 39690926 · DOI 10.1002/cnr2.70087